Comments
Loading...

IDEXX Laboratories Analyst Ratings

IDXXNASDAQ
Logo brought to you by Benzinga Data
$404.02
At close: Apr 15 EDT
$404.02
0.000.00%
Pre-Market: 4:00 PM EDT
Consensus Rating1
Overweight
Highest Price Target1
$650.00
Lowest Price Target1
$420.00
Consensus Price Target1
$534.09

IDEXX Laboratories Analyst Ratings and Price Targets | NASDAQ:IDXX | Benzinga

IDEXX Laboratories Inc has a consensus price target of $534.09 based on the ratings of 11 analysts. The high is $650 issued by Goldman Sachs on January 17, 2024. The low is $420 issued by Stifel on April 14, 2025. The 3 most-recent analyst ratings were released by Stifel, Piper Sandler, and Barclays on April 14, 2025, February 10, 2025, and February 4, 2025, respectively. With an average price target of $483.33 between Stifel, Piper Sandler, and Barclays, there's an implied 19.63% upside for IDEXX Laboratories Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
Nov 24
1
Dec 24
1
Jan
1
2
Feb
0
0
0
0
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stifel
Piper Sandler
Barclays
B of A Securities
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for IDEXX Laboratories

Buy NowGet Alert
04/14/2025Buy Now3.96%Stifel
Jonathan Block71%
$450 → $420MaintainsHoldGet Alert
02/10/2025Buy Now26.23%Piper Sandler
David Westenberg59%
$435 → $510MaintainsNeutralGet Alert
02/04/2025Buy Now28.71%Barclays
Balaji Prasad51%
$481 → $520MaintainsOverweightGet Alert
02/04/2025Buy Now32.42%B of A Securities
Michael Ryskin46%
$475 → $535MaintainsNeutralGet Alert
01/29/2025Buy Now36.13%Morgan Stanley
Erin Wright76%
$559 → $550MaintainsOverweightGet Alert
12/02/2024Buy Now23.76%Leerink Partners
Daniel Clark12%
→ $500Initiates → OutperformGet Alert
11/04/2024Buy Now7.67%Piper Sandler
David Westenberg59%
$520 → $435ReiteratesNeutral → NeutralGet Alert
11/04/2024Buy Now19.05%Barclays
Balaji Prasad51%
$570 → $481MaintainsOverweightGet Alert
10/11/2024Buy Now42.32%JP Morgan
Chris Schott59%
$630 → $575MaintainsOverweightGet Alert
10/10/2024Buy Now23.76%Stifel
Jonathan Block71%
$510 → $500MaintainsHoldGet Alert
08/14/2024Buy Now28.71%Piper Sandler
David Westenberg59%
$600 → $520MaintainsNeutralGet Alert
07/25/2024Buy Now43.56%BTIG
Mark Massaro71%
→ $580Initiates → BuyGet Alert
06/24/2024Buy Now26.23%Stifel
Jonathan Block71%
$520 → $510MaintainsHoldGet Alert
05/14/2024Buy Now47.52%Morgan Stanley
Erin Wright76%
$620 → $596MaintainsOverweightGet Alert
05/02/2024Buy Now41.08%Barclays
Balaji Prasad51%
$655 → $570MaintainsOverweightGet Alert
02/06/2024Buy Now55.93%JP Morgan
Chris Schott59%
$600 → $630MaintainsOverweightGet Alert
02/06/2024Buy Now62.12%Barclays
Balaji Prasad51%
$605 → $655MaintainsOverweightGet Alert
01/30/2024Buy Now29.94%Piper Sandler
David Westenberg59%
→ $525DowngradeOverweight → NeutralGet Alert
01/17/2024Buy Now60.88%Goldman Sachs
Nathan Rich44%
$500 → $650MaintainsBuyGet Alert
11/06/2023Buy Now29.94%Piper Sandler
David Westenberg59%
$520 → $525MaintainsOverweightGet Alert
11/03/2023Buy Now23.76%Goldman Sachs
Nathan Rich44%
$578 → $500MaintainsBuyGet Alert
11/02/2023Buy Now36.13%JP Morgan
Chris Schott59%
$600 → $550MaintainsOverweightGet Alert
11/02/2023Buy Now46.53%Barclays
Balaji Prasad51%
$590 → $592MaintainsOverweightGet Alert
10/30/2023Buy Now13.86%Stifel
Jonathan Block71%
$500 → $460MaintainsHoldGet Alert
09/15/2023Buy Now23.76%Stifel
Jonathan Block71%
$525 → $500MaintainsHoldGet Alert
08/03/2023Buy Now48.51%Morgan Stanley
Erin Wright76%
$590 → $600MaintainsOverweightGet Alert
08/02/2023Buy Now48.51%JP Morgan
Chris Schott59%
$550 → $600MaintainsOverweightGet Alert
08/02/2023Buy Now48.51%Atlantic Equities
Steve Chesney57%
→ $600DowngradeOverweight → NeutralGet Alert
06/07/2023Buy Now48.51%Atlantic Equities
Steve Chesney57%
→ $600ReiteratesOverweight → OverweightGet Alert
05/03/2023Buy Now48.51%Atlantic Equities
Steve Chesney57%
→ $600Reiterates → OverweightGet Alert
03/23/2023Buy Now46.03%Morgan Stanley
Erin Wright76%
$543 → $590MaintainsOverweightGet Alert
02/08/2023Buy Now46.03%Barclays
Balaji Prasad51%
$582 → $590MaintainsOverweightGet Alert
02/07/2023Buy Now36.13%JP Morgan
Chris Schott59%
$525 → $550MaintainsOverweightGet Alert
02/07/2023Buy Now48.51%Atlantic Equities
Steve Chesney57%
$470 → $600MaintainsOverweightGet Alert
01/25/2023Buy Now31.18%Goldman Sachs
Nathan Rich44%
$465 → $530MaintainsBuyGet Alert
11/15/2022Buy Now34.4%Morgan Stanley
Erin Wright76%
$573 → $543MaintainsOverweightGet Alert
11/02/2022Buy Now16.33%Atlantic Equities
Steve Chesney57%
$490 → $470MaintainsOverweightGet Alert
10/17/2022Buy Now11.38%JP Morgan
Chris Schott59%
$525 → $450MaintainsOverweightGet Alert
08/05/2022Buy Now44.05%Barclays
Balaji Prasad51%
$700 → $582MaintainsOverweightGet Alert
08/04/2022Buy Now41.82%Morgan Stanley
Erin Wright76%
$603 → $573MaintainsOverweightGet Alert
08/03/2022Buy Now21.28%Atlantic Equities
Steve Chesney57%
$500 → $490MaintainsOverweightGet Alert
07/26/2022Buy Now3.96%Piper Sandler
David Westenberg59%
$440 → $420MaintainsOverweightGet Alert
07/25/2022Buy Now2.72%Stifel
Jonathan Block71%
$500 → $415DowngradeBuy → HoldGet Alert
07/21/2022Buy Now7.67%Goldman Sachs
Nathan Rice56%
$530 → $435UpgradeNeutral → BuyGet Alert
07/12/2022Buy Now8.91%Piper Sandler
David Westenberg59%
→ $440Initiates → OverweightGet Alert
06/24/2022Buy Now23.76%Stifel
Jonathan Block71%
$575 → $500MaintainsBuyGet Alert
05/19/2022Buy Now31.18%Goldman Sachs
Nathan Rice56%
$615 → $530MaintainsNeutralGet Alert
05/05/2022Buy Now49.25%Morgan Stanley
Erin Wright76%
$732 → $603MaintainsOverweightGet Alert
05/05/2022Buy Now16.33%B of A Securities
Michael Ryskin46%
$550 → $470DowngradeBuy → NeutralGet Alert

FAQ

Q

What is the target price for IDEXX Laboratories (IDXX) stock?

A

The latest price target for IDEXX Laboratories (NASDAQ:IDXX) was reported by Stifel on April 14, 2025. The analyst firm set a price target for $420.00 expecting IDXX to rise to within 12 months (a possible 3.96% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for IDEXX Laboratories (IDXX)?

A

The latest analyst rating for IDEXX Laboratories (NASDAQ:IDXX) was provided by Stifel, and IDEXX Laboratories maintained their hold rating.

Q

When was the last upgrade for IDEXX Laboratories (IDXX)?

A

The last upgrade for IDEXX Laboratories Inc happened on July 21, 2022 when Goldman Sachs raised their price target to $435. Goldman Sachs previously had a neutral for IDEXX Laboratories Inc.

Q

When was the last downgrade for IDEXX Laboratories (IDXX)?

A

The last downgrade for IDEXX Laboratories Inc happened on January 30, 2024 when Piper Sandler changed their price target from N/A to $525 for IDEXX Laboratories Inc.

Q

When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on April 14, 2025 so you should expect the next rating to be made available sometime around April 14, 2026.

Q

Is the Analyst Rating IDEXX Laboratories (IDXX) correct?

A

While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $450.00 to $420.00. The current price IDEXX Laboratories (IDXX) is trading at is $404.02, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch